

# Supplementary Fig. 1

All patients with advanced gastric cancer in 2 institutions during the past 6 years (Sep 1, 2010 to Aug 31, 2016)  
(*n*=1032)

Eligible patients  
(*n*=131)

Analyzed  
(*n*=131)

Patients excluded (*n*=901)

1. Missing weight data over 12 weeks
2. Surgical operation of the gastrointestinal tract within the last 6 months excluding stent placement in the gastrointestinal tract or gastroduodenostomy
3. Weight loss clearly attributable to gastrointestinal obstruction
4. Multiple concurrent active cancers
5. Experience of paracentesis for ascitic fluid at the beginning of first-line chemotherapy